Elite Pharmaceuticals Inc (ELTP)

[ARbigguy1]

Elite's $Billions in market access potential in less than a year!

Approved - generic version of Percocet - QuintilesIMS Health data for the twelve months ending May 31, 2018, the retail sales for the brand and generic products were approximately $500 million.

SOON! - generic version of Norco - $700 million according to IMS Health data.

SOON! - generic version of a synthetic narcotic analgesic - over $40 million in 2016 according to IMS Health data.

SOON! - generic version of OxyContin - IMS reported approximately $2.3 billion in revenue for OxyContin® and its equivalents in 2016.

December 2018 (10 months) to Early 2019 - Elite/SunGen - generic version of an immediate release central nervous system (“CNS”) stimulant - IMS Health data, the branded product and its equivalents had total U.S. sales of more than $400 million for the twelve months ended September 30, 2017.

March 2019 (10 months) - Elite/SunGen - generic version of an extended release CNS stimulant - total U.S. sales of approximately $1.6 billion for the twelve months ended September 30, 2017.

$500 million + $700 Million + $40 million + $2.3 BILLION + $400 million + $1.6 BILLION = $5.54 BILLION market opening up to Elite (ELTP).